{"filing":{"accession_number":"0001193125-26-381879","cik":"0000818686","ticker":"TEVJF","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","form":"8-K","filing_date":"2026-09-03","report_date":"2026-08-31","primary_document":"d174614d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526381879/d174614d8k.htm"},"events":[{"id":31591,"run_id":28999,"accession_number":"0001193125-26-381879","anchor_item_number":"3.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"This disclosure concerns a material modification to the rights of ADS holders through Amendment No. 1 to the Deposit Agreement, which establishes a mandatory exchange mechanism converting ADSs to ordinary shares upon termination of the ADS program and listing on NYSE. While the event involves a capital structure change, it is fundamentally a governance/shareholder-rights matter—the amendment modifies the contractual rights and economic interests of a class of security holders. This does not fit the specific categories of dilutive issuance, debt issuance, or other financial events, making governance_other the most appropriate classification.","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34521,"accession_number":"0001193125-26-381879","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure concerns a material modification to the rights of ADS holders through Amendment No. 1 to the Deposit Agreement, which establishes a mandatory exchange mechanism converting ADSs to ordinary shares upon termination of the ADS program and listing on NYSE. While the event involves a capital structure change, it is fundamentally a governance/shareholder-rights matter—the amendment modifies the contractual rights and economic interests of a class of security holders. This does not fit the specific categories of dilutive issuance, debt issuance, or other financial events, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:13:34.916541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34521,"accession_number":"0001193125-26-381879","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure concerns a material modification to the rights of ADS holders through Amendment No. 1 to the Deposit Agreement, which establishes a mandatory exchange mechanism converting ADSs to ordinary shares upon termination of the ADS program and listing on NYSE. While the event involves a capital structure change, it is fundamentally a governance/shareholder-rights matter—the amendment modifies the contractual rights and economic interests of a class of security holders. This does not fit the specific categories of dilutive issuance, debt issuance, or other financial events, making governance_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:13:34.916541+00:00","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-09-03"}]}